LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Pathologic Outcomes of Gleason 6 Favorable Intermediate‐Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance

Photo from wikipedia

&NA; We examined the pathologic outcomes of 2807 men with Gleason 6 favorable intermediate‐risk (FIR) prostate cancer treated with radical prostatectomy; 25.5% of patients with prostate‐specific antigen of 10 to… Click to show full abstract

&NA; We examined the pathologic outcomes of 2807 men with Gleason 6 favorable intermediate‐risk (FIR) prostate cancer treated with radical prostatectomy; 25.5% of patients with prostate‐specific antigen of 10 to 20 ng/mL and 12.4% with cT2b to T2c stage harbored higher grade or stage disease, suggesting that Gleason 6 FIR patients with cT2b to T2c tumors might generally be reasonable candidates for active surveillance. Background: The safety of active surveillance (AS) for Gleason 6 favorable intermediate‐risk (FIR) prostate cancer is unknown. To provide guidance, we examined the incidence and predictors of upgrading or upstaging for Gleason 6 FIR patients treated with radical prostatectomy. Patients and Methods: We identified 2807 men in the National Cancer Database diagnosed from 2010 to 2012 with Gleason 6 FIR disease (<50% positive biopsy cores [PBC] with either prostate‐specific antigen [PSA] of 10‐20 ng/mL or cT2b‐T2c disease) treated with radical prostatectomy. Logistic regression was used to identify predictors of upgrading (Gleason 3+4 with tertiary Gleason 5 or Gleason ≥4+3) or upstaging (pT3‐4/N1). Results: Fifty‐seven percent of the cohort had PSA of 10 to 20 ng/mL; 25.5% patients with PSA of 10 to 20 ng/mL and 12.4% with cT2b to T2c disease were upgraded or upstaged. In multivariable analysis, predictors of upgrading or upstaging included increasing age (P = .026), PSA (P = .001), and percent PBC (P < .001), and black race versus white (P = .035) for patients with PSA of 10 to 20 ng/mL and increasing PSA (P = .001) and percent PBC (P < .001) for patients with cT2b to T2c disease. Men with PSA of 15.0 to 20.0 ng/mL or 37.5% to 49.9% PBC with PSA of 10 to 20 ng/mL had >30% risk of upgrading or upstaging, whereas cT2b to T2c patients with <12.5% PBC or PSA <5.0 ng/mL had <10% risk. Conclusion: We found that Gleason 6 FIR patients with cT2b to T2c tumors had a low risk of harboring higher grade or stage disease and would be reasonable AS candidates, whereas patients with PSA of 10 to 20 ng/mL had a high risk and might generally be poor AS candidates.

Keywords: prostate; treated radical; risk; cancer; ct2b t2c; radical prostatectomy

Journal Title: Clinical Genitourinary Cancer
Year Published: 2018

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.